INFORMATIONAL PURPOSES ONLY. Not medical, legal, or travel advice. Verify with official sources before acting. See corrections log.
State-by-state comparison: limit practitioner scope for cell therapies. Interactive map and sortable table for all 50 US states.
| State | Value | Verified | Source |
|---|---|---|---|
| Alaska | No explicit state provision; federal framework applies. | 2026-10-09 | Source |
| Alabama | No explicit state provision; federal framework applies. | 2026-10-09 | Source |
| Arkansas | No explicit state provision; federal framework applies. | 2026-10-09 | Source |
| Arizona | No explicit state provision; federal framework applies. | 2026-10-09 | Source |
| California | 2026-10-09 | Source | |
| Colorado | No explicit state provision; federal framework applies. | 2026-10-09 | Source |
| Connecticut | No explicit state provision; federal framework applies. | 2026-10-09 | Source |
| District of Columbia | No explicit state provision; federal framework applies. | 2026-10-09 | Source |
| Delaware | No explicit state provision; federal framework applies. | 2026-10-09 | Source |
| Florida | 2026-10-09 | Source | |
| Georgia | 2026-10-09 | Source | |
| Hawaii | No explicit state provision; federal framework applies. | 2026-10-09 | Source |
| Iowa | No explicit state provision; federal framework applies. | 2026-10-09 | Source |
| Idaho | No explicit state provision; federal framework applies. | 2026-10-09 | Source |
| Illinois | No explicit state provision; federal framework applies. | 2026-10-09 | Source |
| Indiana | No explicit state provision; federal framework applies. | 2026-10-09 | Source |
| Kansas | No explicit state provision; federal framework applies. | 2026-10-09 | Source |
| Kentucky | No explicit state provision; federal framework applies. | 2026-10-09 | Source |
| Louisiana | No explicit state provision; federal framework applies. | 2026-10-09 | Source |
| Massachusetts | No explicit state provision; federal framework applies. | 2026-10-09 | Source |
| Maryland | No explicit state provision; federal framework applies. | 2026-10-09 | Source |
| Maine | No explicit state provision; federal framework applies. | 2026-10-09 | Source |
| Michigan | No explicit state provision; federal framework applies. | 2026-10-09 | Source |
| Minnesota | No explicit state provision; federal framework applies. | 2026-10-09 | Source |
| Missouri | No explicit state provision; federal framework applies. | 2026-10-09 | Source |
| Mississippi | Requires a physician's prescription or recommendation; statute does not specify who administers. Product must be IRB-approved or in an FDA/NIH-approved protocol, have completed phase 1, and remain under investigation. | 2026-10-09 | Source |
| Montana | No stem-cell-specific provision. Under the general Right to Try Act, experimental treatments may be provided by physicians, prescribing APRNs, physician assistants, and registered nurses at experimental treatment centers. | 2026-10-09 | Source |
| North Carolina | Physician must administer; protocol approved by an IRB (affiliated with a medical school or its affiliated facility), with annual IRB reports to the NC Medical Board. | 2026-10-09 | Source |
| North Dakota | No explicit state provision; federal framework applies. | 2026-10-09 | Source |
| Nebraska | 2026-10-09 | Source | |
| New Hampshire | No explicit state provision; federal framework applies. | 2026-10-09 | Source |
| New Jersey | No explicit state provision; federal framework applies. | 2026-10-09 | Source |
| New Mexico | No explicit state provision; federal framework applies. | 2026-10-09 | Source |
| Nevada | No explicit state provision; federal framework applies. | 2026-10-09 | Source |
| New York | No explicit state provision; federal framework applies. | 2026-10-09 | Source |
| Ohio | No explicit state provision; federal framework applies. | 2026-10-09 | Source |
| Oklahoma | No explicit state provision; federal framework applies. | 2026-10-09 | Source |
| Oregon | No explicit state provision; federal framework applies. | 2026-10-09 | Source |
| Pennsylvania | No explicit state provision; federal framework applies. | 2026-10-09 | Source |
| Rhode Island | No explicit state provision; federal framework applies. | 2026-10-09 | Source |
| South Carolina | No explicit state provision; federal framework applies. | 2026-10-09 | Source |
| South Dakota | No explicit state provision; federal framework applies. | 2026-10-09 | Source |
| Tennessee | Physicians (licensed under Tenn. Code Ann. title 63, chapter 6 or 9, i.e. MD or DO), for treatments within the physician's scope of practice; products must come from compliant facilities. | 2026-10-09 | Source |
| Texas | MD/DO; IRB oversight | 2026-10-09 | Source |
| Utah | 2026-10-09 | Source | |
| Virginia | No explicit state provision; federal framework applies. | 2026-10-09 | Source |
| Vermont | No stem-cell-specific limit on who may administer; notice and disclosure duties apply to any health care practitioner licensed by the Board of Medical Practice or the Office of Professional Regulation. | 2026-10-09 | Source |
| Washington | 2026-10-09 | Source | |
| Wisconsin | No explicit state provision; federal framework applies. | 2026-10-09 | Source |
| West Virginia | No explicit state provision; federal framework applies. | 2026-10-09 | Source |
| Wyoming | Physicians licensed by the Wyoming state board of medicine (not physician assistants) who are registered with the board to provide stem cell therapy; administered by or under direct supervision of a physician. | 2026-10-09 | Source |
Add an interactive map to your site. Always stays current.